Table 3.
Multivariable models of survival stratified by low, intermediate, and high-risk classification.
| Covariate | Low Risk | Intermediate Risk | High Risk |
|---|---|---|---|
| Follow-up months | |||
| Median (range) | 65.12 (0.00–188.52) | 66.30 (0.03–187.33) | 62.88 (0.00–190.26) |
| Chemotherapy | |||
| No | Referent | Referent | Referent |
| Yes | 1.10 (0.85–1.42) | 0.74 (0.62–0.89)* | 0.78 (0.71–0.85)* |
| Age | |||
| <40 | Referent | Referent | Referent |
| 40–49 | 1.52 (0.90–2.57) | 1.17 (0.79–1.74) | 1.16 (0.96–1.42) |
| 50–59 | 3.89 (2.46–6.15)* | 1.44 (0.96–2.16) | 1.38 (1.14–1.66)* |
| 60–69 | 4.79 (2.93–7.85)* | 2.01 (1.36–2.97)* | 1.64 (1.34–2.00)* |
| ≥70 | 9.86 (5.85–16.63)* | 3.63 (2.43–5.44)* | 3.45 (2.81–4.25)* |
| Race | |||
| White | Referent | Referent | Referent |
| Black | 0.86 (0.55–1.34) | 1.31 (0.91–1.88) | 1.50 (1.26–1.78)* |
| Hispanic | 0.91 (0.55–1.49) | 0.56 (0.32–0.98)* | 1.01 (0.83–1.23) |
| Other/unknown | 0.80 (0.46–1.39) | 1.04 (0.70–1.55) | 1.02 (0.85–1.23) |
| Insurance | |||
| Private | Referent | Referent | Referent |
| Medicaid | 2.68 (1.76–4.07)* | 1.82 (1.17–2.83)* | 1.48 (1.20–1.82)* |
| Medicare | 1.66 (1.22–2.27)* | 1.48 (1.16–1.90)* | 1.22 (1.08–1.38)* |
| Uninsured | 2.23 (1.42–3.48)* | 1.47 (0.94–2.29) | 1.16 (0.93–1.45) |
| Other government/unknown | 1.52 (0.97–2.38) | 1.49 (1.01–2.20)* | 1.25 (0.99–1.57) |
| Facility Location | |||
| Eastern | Referent | Referent | Referent |
| Midwest | 1.22 (0.95–1.57) | 1.32 (1.03–1.68)* | 1.05 (0.93–1.19) |
| South | 1.19 (0.91–1.56) | 1.26 (0.98–1.60) | 1.11 (0.98–1.26) |
| West | 1.27 (0.93–1.72) | 0.89 (0.65–1.20) | 0.99 (0.87–1.14) |
| Facility Type | |||
| Community cancer | Referent | Referent | Referent |
| Academic/research | 1.53 (1.07–2.20)* | 1.03 (0.74–1.43) | 1.06 (0.90–1.24) |
| Comprehensive community cancer | 1.45 (1.02–2.05)* | 0.98 (0.71–1.36) | 1.04 (0.89–1.22) |
| Other | – ╪ | 2.73 (1.87–3.98)* | 1.06 (0.88–1.29) |
| Urban/Rural | |||
| Metropolitan | Referent | Referent | Referent |
| Urban | 1.08 (0.82–1.42) | 1.03 (0.82–1.30) | 1.04 (0.92–1.17) |
| Rural | 0.88 (0.45–1.71) | 0.59 (0.27–1.29) | 1.37 (1.04–1.80)* |
| Unknown | 1.06 (0.65–1.74) | 1.76 (1.27–2.45)* | 1.57 (1.33–1.85)* |
| Histology | |||
| Serous | Referent | Referent | Referent |
| Mucinous | 1.32 (1.00–1.75) | 1.13 (0.89–1.45) | 1.14 (1.00–1.30) |
| Endometrioid | 0.85 (0.64–1.14) | 0.80 (0.64–1.00) | 0.73 (0.66–0.82)* |
| Clear cell | - | - | 1.07 (0.95–1.20) |
| Transitional cell | - ╪ | - ╪ | 0.99 (0.61–1.59) |
| Epithelial tumor NOS | 1.50 (1.01–2.21)* | 0.81 (0.57–1.16) | 1.04 (0.90–1.21) |
| Grade | |||
| 1 | - | - | Referent |
| 2 | - | - | 1.52 (1.30–1.77)* |
| 3 | - | - | 1.96 (1.69–2.28)* |
| Unknown | - | - | 1.52 (1.29–1.79)* |
| Stage | |||
| 1A | Referent | Referent | Referent |
| 1B | 1.20 (0.86–1.69) | 1.61 (1.23–2.12)* | 1.37 (1.14–1.64)* |
| 1C | - | - | 1.53 (1.37–1.71)* |
| Lymph nodes examined | |||
| Yes | Referent | Referent | Referent |
| No | 1.54 (1.27–1.87)* | 1.45 (1.20–1.73)* | 1.62 (1.49–1.76)* |
| Unknown | 1.56 (0.63–3.85) | 1.27 (0.56–2.88) | 1.47 (1.04–2.08)* |
| Year of Diagnosis | |||
| 1998 | Referent | Referent | Referent |
| 1999 | 1.37 (0.95–1.96) | 1.19 (0.80–1.76) | 0.85 (0.71–1.01) |
| 2000 | 1.04 (0.69–1.55) | 1.42 (0.99–2.05) | 0.72 (0.59–0.87)* |
| 2001 | 1.18 (0.79–1.76) | 1.11 (0.75–1.65) | 0.89 (0.76–1.05) |
| 2002 | 1.38 (0.90–2.11) | 1.14 (0.78–1.67) | 0.92 (0.77–1.10) |
| 2003 | 1.52 (0.99–2.33) | 0.97 (0.63–1.51) | 0.97 (0.81–1.16) |
| 2004 | 1.57 (1.04–2.37)* | 1.33 (0.85–2.08) | 0.85 (0.71–1.03) |
| 2005 | 1.38 (0.90–2.11) | 1.43 (0.95–2.14) | 0.87 (0.72–1.04) |
| 2006 | 1.52 (0.95–2.43) | 0.96 (0.59–1.58) | 0.95 (0.77–1.15) |
| 2007 | 1.30 (0.77–2.22) | 1.08 (0.69–1.70) | 0.99 (0.81–1.20) |
| 2008 | 1.00 (0.56–1.79) | 1.04 (0.61–1.77) | 0.90 (0.74–1.08) |
| 2009 | 1.17 (0.62–2.24) | 1.05 (0.61–1.81) | 0.93 (0.73–1.18) |
| 2010 | 0.91 (0.44–1.87) | 1.00 (0.49–2.04) | 1.03 (0.79–1.34) |
| 2011 | 0.87 (0.37–2.04) | 1.06 (0.51–2.18) | 1.13 (0.86–1.50) |
Adjusted hazard ratio (95% confidence interval).
Age, race, insurance status, facility region, facility type, facility location, histology, stage, lymph node examination, and year of diagnosis were included in the marginal Cox proportional hazard models accounting for facility-level clustering. Grade was further adjusted for in the high-risk group.
╪
Non-estimable.
1,833 patients missing follow-up time, vital status, or facility identifier were excluded; 3,851, 3,502, and 12,572 patients were modeled in the low, intermediate, and high-risk groups.